Entrada Therapeutics (TRDA) Other Gross PP&E Adjustments (2022 - 2025)
Historic Other Gross PP&E Adjustments for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to -$43.5 million.
- Entrada Therapeutics' Other Gross PP&E Adjustments rose 2013.39% to -$43.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.5 million, marking a year-over-year increase of 2013.39%. This contributed to the annual value of -$53.2 million for FY2024, which is 1951.58% up from last year.
- Entrada Therapeutics' Other Gross PP&E Adjustments amounted to -$43.5 million in Q3 2025, which was up 2013.39% from -$44.5 million recorded in Q2 2025.
- Entrada Therapeutics' Other Gross PP&E Adjustments' 5-year high stood at -$1.0 million during Q1 2023, with a 5-year trough of -$72.9 million in Q2 2023.
- Over the past 4 years, Entrada Therapeutics' median Other Gross PP&E Adjustments value was -$47.4 million (recorded in 2025), while the average stood at -$42.9 million.
- As far as peak fluctuations go, Entrada Therapeutics' Other Gross PP&E Adjustments soared by 9547.89% in 2023, and later plummeted by 594254.69% in 2024.
- Entrada Therapeutics' Other Gross PP&E Adjustments (Quarter) stood at -$15.5 million in 2022, then plummeted by 327.26% to -$66.1 million in 2023, then increased by 19.52% to -$53.2 million in 2024, then grew by 18.13% to -$43.5 million in 2025.
- Its Other Gross PP&E Adjustments was -$43.5 million in Q3 2025, compared to -$44.5 million in Q2 2025 and -$47.4 million in Q1 2025.